Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun;27(6):734-747.
doi: 10.1007/s11912-025-01678-y. Epub 2025 Apr 28.

Rare Genetic and Uncommon Morphological Entities in Adults with Acute Myeloid Leukemia

Affiliations
Review

Rare Genetic and Uncommon Morphological Entities in Adults with Acute Myeloid Leukemia

Xavier Thomas. Curr Oncol Rep. 2025 Jun.

Abstract

Purpose of review: Despite differences in the various classification systems of acute myeloid leukemia (AML), rare entities can be identified according to clinical, biological or morphological characteristics. Uncommon AML defined on specific morphological criteria and/or genetic abnormalities were considered if occurring with a frequency of ≤ 5% in adult patients with AML.

Recent findings: Most of uncommon AML are characterized by a poor outcome with the standard treatment approaches. During the last decade, several therapeutic drugs with promising investigational approaches have been used in therapeutic regimens in both frontline and relapsed/refractory AML and represent a positive potential benefit for some rare entities displaying specific molecular lesions. Several rare subtypes can be identified in adult patients with AML. In this descriptive review, we assess the available information for these rare entities and summarized treatments that could be proposed especially according to their genetic characterization.

Keywords: Diagnosis; Genetic profile; Morphological criteria; Outcome; Rare leukemias; Treatment.

PubMed Disclaimer

Conflict of interest statement

Declarations. Human and Animal Rights and Informed Consent: This article does not contain any studies with human or animal subjects performed by the author. Competing Interests: The author declares no competing interests.

Similar articles

References

    1. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47. - PubMed - PMC - DOI
    1. Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–77. - PubMed - DOI
    1. Attardi E, Savi A, Borsellino B, Piciocchi A, Cipriani M, Ottone T, et al. Applicability of 2022 classifications of acute myeloid leukemia in the real-world setting. Blood Adv. 2023;7:5122–31. - PubMed - PMC - DOI
    1. Thomas XG. Rare acute leukemias. SM Ansell, editor Rare hematological malignancies. Springer. 2008; 149–191.
    1. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukaemia. N Engl J Med. 2016;374:2209–21. - PubMed - PMC - DOI

MeSH terms

LinkOut - more resources